title: [Neoadjuvant intraarterial chemotherapy with nedaplatin, peplomycin and mitomycin C for advanced cervical cancer].
abstract: The aim of the present study was to examine the usefulness of neoadjuvant intraarterial chemotherapy (NAC) using nedaplatin as key drug to improve the prognosis in case of advanced cervical cancer. Twenty-five cases of advanced cervical cancer (15 cases of stage II with high risks, 10 of stage III, referred to as the 254-S group) treated by NAC using nedaplatin, mitomycin C and peplomycin were compared with 30 cases (22 cases of stage II with high risks, 8 of stage III, referred to as the CDDP group) treated using cisplatin and mitomycin C which is the conventional regimen, in terms of measurable response, pathological response, rate of lymph node metastasis, cumulative survival rate, side effects and relapse style. According to the evaluation by measurable responses, the response rate was 90% (CR 52%) in the 254-S group and 75% (CR 15%) in the CDDP group. For pathological response of the specimen, the CR rate was 16% in the 254-S group and 23% in the CDDP group. The rate of lymph node metastasis extracted surgically was 33% and 41%, respectively. The cumulative survival rate in the 254-S group was about 10% better than in the CDDP group, but no significant difference was found. Leucopenia of both groups was of the same grade. In the 254-S group, although thrombocytopenia was more critical than in the CDDP group, there was a slight tendency to kidney toxicity. The locoregional recurrence rate was 12% in the 254-S group and 30% in the CDDP group. The distant metastasis rate was 16% and 27%, respectively. Although neoadjuvant intraarterial chemotherapy using nedaplatin as a key drug was useful to improve the prognosis of advanced cervical cancer, measures against recurrence outside the pelvis and individualization of medical treatment were considered to lead to a further improvement of the prognosis.
authors.affiliation: Dept. of Obstetrics and Gynecology, Toride Kyodo Hospital.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Umeki
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Mikiko
authors.initials: M
authors.lastname: Tsugata
authors.forename: Kimio
authors.initials: K
authors.lastname: Wakana
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Somekawa
authors.forename: Kouji
authors.initials: K
authors.lastname: Shimabukuro
authors.forename: Motohiro
authors.initials: M
authors.lastname: Ohara
authors.forename: Tomoko
authors.initials: T
authors.lastname: Terauchi
authors.forename: Mikio
authors.initials: M
authors.lastname: Ichimura
authors.forename: Isao
authors.initials: I
authors.lastname: Otsuka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Aso
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008207:Lymphatic Metastasis; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017663:Peplomycin / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds; D016685:Mitomycin; D017663:Peplomycin; C053989:nedaplatin; D002945:Cisplatin